2024-516869-36-00招募中1 期
A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 25
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Information Desk
Scientific
Exscientia AI Limited
研究点 (2)
Loading locations...
相似试验
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors2024-515504-39-00Centre Hospitalier Universitaire De Nantes6
招募中
1 期
An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)2023-508444-22-01Region Midtjylland30
已完成
1 期
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapy2024-511853-23-00Oncoinvent ASA54
招募中
1 期
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis2023-503679-12-00Janssen - Cilag International75
已完成
1 期
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy ParticipantsRespiratory syncytial virus infection2022-502926-42-00Merck Sharp & Dohme LLC32